These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2909725)

  • 1. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Veber DE; Anderson PS; Freidinger RM
    J Med Chem; 1989 Jan; 32(1):13-6. PubMed ID: 2909725
    [No Abstract]   [Full Text] [Related]  

  • 2. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
    Castro JL; Broughton HB; Russell MG; Rathbone D; Watt AP; Ball RG; Chapman KL; Patel S; Smith AJ; Marshall GR; Matassa VG
    J Med Chem; 1997 Aug; 40(16):2491-501. PubMed ID: 9258356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex.
    Harper EA; Griffin EP; Shankley NP; Black JW
    Br J Pharmacol; 1999 Mar; 126(6):1496-503. PubMed ID: 10217545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260.
    Lotti VJ; Chang RS
    Eur J Pharmacol; 1989 Mar; 162(2):273-80. PubMed ID: 2721567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benzodiazepine analogues L365,260 and L364,718 as gastrin and pancreatic CCK receptor antagonists.
    Huang SC; Zhang L; Chiang HC; Wank SA; Maton PN; Gardner JD; Jensen RT
    Am J Physiol; 1989 Jul; 257(1 Pt 1):G169-74. PubMed ID: 2473653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC
    J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of ex vivo binding to estimate brain penetration and central activity of CCK-B antagonists.
    Patel S; Chapman KL; Smith AJ; Heald A; Freedman SB
    Ann N Y Acad Sci; 1994 Mar; 713():360-3. PubMed ID: 8185188
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
    Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
    J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 1,5-benzodiazepines as CCK-B ligands. Effect of aryl-carbamic substituents at the C-3 position together with halogen substitution on the benzo-fused ring.
    Tranquillini ME; Cassarà PG; Corsi M; Curotto G; Donati D; Finizia G; Pentassuglia G; Polinelli S; Tarzia G; Ursini A; van Amsterdam FT
    Arch Pharm (Weinheim); 1997 Nov; 330(11):353-7. PubMed ID: 9431027
    [No Abstract]   [Full Text] [Related]  

  • 10. Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.
    Bock MG; DiPardo RM; Newton RC; Bergman JM; Veber DF; Freedman SB; Smith AJ; Chapman KL; Patel S; Kemp JA
    Bioorg Med Chem; 1994 Sep; 2(9):987-98. PubMed ID: 7712133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry.
    Hagishita S; Seno K; Kamata S; Haga N; Ishihara Y; Ishikawa M; Shimamura M
    Bioorg Med Chem; 1997 Jul; 5(7):1433-46. PubMed ID: 9377103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of N1-substituted-3-propyl-1,4-benzodiazepine-2-ones as cholecystokinin (CCK2) receptor ligands.
    Lattmann E; Sattayasai J; Billington DC; Poyner DR; Puapairoj P; Tiamkao S; Airarat W; Singh H; Offel M
    J Pharm Pharmacol; 2002 Jun; 54(6):827-34. PubMed ID: 12078999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
    Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
    J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Veber DF; Freidinger RM; Chang RS; Lotti VJ
    J Med Chem; 1988 Jan; 31(1):176-81. PubMed ID: 3336017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
    Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD
    Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Veber DF; Freidinger RM; Chang RS; Chen TB; Lotti VJ
    J Med Chem; 1990 Jan; 33(1):450-5. PubMed ID: 2153212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
    Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ
    Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
    Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
    J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the variation in the action of L-365,260 at CCKB/gastrin receptors in rat, guinea-pig and mouse isolated gastric tissue assays.
    Roberts SP; Harper EA; Watt GF; Gerskowitch VP; Hull RA; Shankley NP; Black JW
    Br J Pharmacol; 1996 Aug; 118(7):1779-89. PubMed ID: 8842444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological activity of analogues of YM022. Novel (3-amino substituted phenyl)urea derivatives of 1,4-benzodiazepin-2-one as gastrin/cholecystokinin-B receptor antagonists.
    Satoh M; Okamoto Y; Koshio H; Ohta M; Nishida A; Akuzawa S; Miyata K; Mase T; Semple G
    Chem Pharm Bull (Tokyo); 1996 Jul; 44(7):1412-4. PubMed ID: 8706146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.